X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
certolizumab pegol (1017) 1017
humans (912) 912
infliximab (537) 537
adalimumab (477) 477
tumor necrosis factor-alpha - antagonists & inhibitors (428) 428
female (387) 387
gastroenterology & hepatology (383) 383
crohn's disease (353) 353
treatment outcome (331) 331
male (327) 327
crohn disease - drug therapy (305) 305
adult (299) 299
antibodies, monoclonal - therapeutic use (285) 285
rheumatoid arthritis (275) 275
double-blind (272) 272
inflammatory-bowel-disease (270) 270
middle aged (266) 266
rheumatology (257) 257
polyethylene glycols - therapeutic use (252) 252
immunoglobulin fab fragments - therapeutic use (240) 240
maintenance therapy (233) 233
arthritis, rheumatoid - drug therapy (211) 211
pharmacology & pharmacy (203) 203
crohns-disease (202) 202
inflammatory bowel disease (193) 193
antibodies, monoclonal, humanized - therapeutic use (192) 192
antirheumatic agents - therapeutic use (191) 191
antibodies, monoclonal, humanized (189) 189
etanercept (181) 181
rheumatoid-arthritis (179) 179
therapy (175) 175
certolizumab pegol - therapeutic use (153) 153
ulcerative colitis (150) 150
immunosuppressive agents - therapeutic use (149) 149
inflammatory bowel diseases - drug therapy (146) 146
anti-inflammatory agents - therapeutic use (137) 137
monoclonal-antibody (129) 129
efficacy (125) 125
ulcerative-colitis (123) 123
aged (122) 122
placebo-controlled trial (121) 121
tumor necrosis factor (121) 121
anti-tnf (119) 119
methotrexate (115) 115
drug therapy (113) 113
monoclonal antibodies (112) 112
arthritis (108) 108
tumor-necrosis-factor (108) 108
antibodies, monoclonal - adverse effects (107) 107
safety (107) 107
young adult (107) 107
drug therapy, combination (106) 106
polyethylene glycols - adverse effects (106) 106
remission (106) 106
immunoglobulin fab fragments - adverse effects (105) 105
severity of illness index (105) 105
remission induction (104) 104
necrosis-factor-alpha (103) 103
quality-of-life (92) 92
animals (91) 91
tumor necrosis factor-tnf (91) 91
crohn’s disease (90) 90
immunology (88) 88
randomized controlled trials as topic (88) 88
abridged index medicus (87) 87
care and treatment (87) 87
certolizumab (87) 87
antibodies, monoclonal, humanized - adverse effects (86) 86
antitumor necrosis factor (86) 86
biological products - therapeutic use (85) 85
patients (85) 85
double-blind method (82) 82
tumor necrosis factor-alpha - immunology (82) 82
clinical-response (81) 81
medicine, general & internal (81) 81
adalimumab - therapeutic use (79) 79
gastrointestinal agents - therapeutic use (79) 79
medicine & public health (79) 79
risk factors (79) 79
clinical trials (78) 78
randomized-trial (78) 78
biologics (77) 77
antirheumatic agents - adverse effects (76) 76
health aspects (76) 76
infliximab - therapeutic use (74) 74
methotrexate - therapeutic use (73) 73
golimumab (72) 72
psoriasis (72) 72
adolescent (71) 71
pregnancy (71) 71
analysis (69) 69
immunosuppressive agents - adverse effects (69) 69
certolizumab pegol - adverse effects (68) 68
quality of life (68) 68
tnf inhibitors (68) 68
natalizumab (67) 67
retrospective studies (67) 67
rheumatoid factor (67) 67
time factors (67) 67
psoriatic arthritis (65) 65
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1205) 1205
German (24) 24
Spanish (17) 17
Russian (14) 14
Japanese (10) 10
French (9) 9
Polish (4) 4
Italian (3) 3
Czech (2) 2
Hungarian (2) 2
Portuguese (2) 2
Croatian (1) 1
Danish (1) 1
Korean (1) 1
Slovak (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


mAbs, ISSN 1942-0862, 03/2010, Volume 2, Issue 2, pp. 137 - 147
Certolizumab pegol (Cimzia®) is currently the only PEGylated anti-TNFα biologic approved for the treatment of rheumatoid arthritis and Crohn disease... 
Binding | Proteins | Landes | Calcium | Bioscience | Biology | Cell | Cycle | Cancer | Organogenesis | Crohn disease | TNFα | Methotrexate | Certolizumab pegol | Rheumatoid arthritis | PEGylated | RHEUMATOID-ARTHRITIS | MEDICINE, RESEARCH & EXPERIMENTAL | certolizumab pegol | TNF alpha | methotrexate | rheumatoid arthritis | ANTIBODY FRAGMENTS | TUMOR-NECROSIS-FACTOR | THERAPY | CDP870 | INFLIXIMAB
Journal Article
Arthritis & rheumatology (Hoboken, N.J.), ISSN 2326-5191, 09/2018, Volume 70, Issue 9, pp. 1399 - 1407
Journal Article
Journal Article
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2007, Volume 357, Issue 3, pp. 239 - 250
Journal Article
Journal Article
Journal Article
Rheumatology (Oxford, England), ISSN 1462-0332, 2017, Volume 56, Issue 9, pp. 1498 - 1509
Journal Article
Journal Article
Journal Article
Journal Article